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available in Brazil for preventing skeletal events (SE) in breast
cancer patients with bone metastasis. METHODS: Indirect
comparison of different clinical trials published do not allow us
to consider that exist an efﬁcacy difference among ibandronate
acid, zoledronic acid and pamidronic acid (e.g.: Body et al.
2004; Rosen et al. 2003; Theriault et al. 1999). In our analysis
only direct costs were considered. The indirect costs of treating
SE were not estimated. For direct costs calculations we assumed
the reduction in analgesics usage reported by De Cock et a.
2005 (Ibandronic acid: 7% reduction vs. Comparators: 3%
reduction). The time horizon of the analysis was 14 months
which represents the average overall survival of patients
(Hotton J et al. 2004). Therefore discounting was not applied.
The payer perspective was adopted under the Brazilian setting.
A one-way sensitivity analysis was conducted. RESULTS:
Results show that ibandronic acid offers the lowest treatment
cost, followed by pamidronic acid and zoledronic acid (R$
10,301, R$ 10,906 and R$ 12,829). Results were sensitive to
drug prices. CONCLUSION: Results suggest ibandronate acid
as a cost-saving alternative with better safety proﬁle when com-
pared to zoledronic acid and pamidronic acid under the Private
Healthcare System perspective in Brazil.
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OBJECTIVES: Navelbine® (Vinorelbine) Oral is an orally
administered formulation of chemotherapy (CT) recently intro-
duced in Italy in the treatment of NSCLC (Non Small Cell Lung
Cancer) and Metastatic Breast Cancer. The purpose of this study
is to evaluate the economic consequences of the impact on phar-
macy, nursing time and patient waiting time of a switch from IV
to oral CT in the treatment of NSCLC. METHODS: Cost-
minimisation analysis was developed in order to evaluate the
times required to deliver IV vinorelbine and oral vinorelbine. The
comparison was made in two settings with different patient path-
ways, in the Cancer Center Unit of Istituto Nazionale dei Tumori,
Milan and Azienda Ospedaliera di Busto Arsizio, Varese. A stop-
watch was used to time elements of essential processes (phar-
macy preparation and chemotherapy administration) and patient
waiting time for the delivery of a single dose of chemotherapy, in
order to build an hypothetic diagnostic and therapeutic pathway
and to describe different phases, times and costs for each formu-
lation. RESULTS: Administration of Vinorelbine Oral was less
time consuming in both Cancer Centres. In the base case sce-
nario, total costs were €171.75 for Oral Vinorelbine (60 mg/m2)
versus €214.84 for IV Vinorelbine (25 mg/m2); for Oral Vinorel-
bine (80 mg/m2) versus IV Vinorelbine (30 mg/m2) costs were
€240.46 and €232.82 respectively. Productivity loss and patient
waiting time were key drivers to our cost minimisation analysis.
Results were submitted to a Sensitivity Analysis. CONCLU-
SION: Delivery of oral CT is less resource intensive and time
consuming than IV CT and reduces overall patient waiting in
hospital. A switch from Vinorelbine IV to Oral formulation with
home administration could increase the capacity of the Day-
Hospital Unit, the number of prescriptions prepared by phar-
macy and thereafter a reduction of the patient waiting list wich is
associated with a global cost reduction.
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OBJECTIVES: The purpose of this study was to compare the
costs of the drug, drug administration and managing of adverse
events (AEs) using erlotinib, docetaxel and pemetrexed as second
line therapy in non-small cell lung cancer (NSCLC), in the Italian
hospital setting. METHODS: Since a clinical study comparing
the three therapies is not available, the major clinical ﬁndings
from randomized trials of each drug were used showing that all
three chemotherapies have comparable efﬁcacy results. Therefore
a cost-minimization analysis was performed. Costs from the
hospital perspective were calculated according to Italian clinical
practice. Consumption of each chemotherapy was based on
respective clinical trial, while to estimate the resources used in the
AEs and for the drug administration a Delphi panel of experts
was structured. In order to allow a comparison between an oral
daily therapy (erlotinib) and infusion therapies administered
every 21 days (docetaxel and pemetrexed), costs were computed
on a monthly base. RESULTS: The total per-patient cost for
erlotinib was €1669, €2569 for docetaxel and €3324 for pemetr-
exed for one month therapy from the hospital perspective. The
cost of AEs represents the 8%, 18%, and 3% of the total cost for
erlotinib, docetaxel and pemetrexed. Sensitivity analysis showed
that no reasonable changes in the quantity and cost of services
reduced the savings associated with erlotinib by more than 33%.
CONCLUSION: A cost-minimization analysis was performed to
assess the cost of three second line chemotherapies in non-small
cell lung cancer. The less costly alternative was erlotinib which
could produce savings between 40% anD 50% of total hospital
costs in Italy.
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OBJECTIVES: To value the use of resources and costs linked
with different presentations of oxaliplatin: lyophilised powder
and concentrated solution. METHODS: A cost-minimization
analysis was conducted with the Spanish hospital’s perspective.
Time consumption and use of resources linked with the prepa-
ration of the products were obtained from a study conducted in
a cancer center in France. The preparation was performed
according to standard clinical practice and several measures were
taken to avoid any bias in the process. Spanish unitary costs were
applied to all resource measures: technicianxs time, consumables
(needles, syringes, water, tampon gauze and air intake), using
cost data from a Spanish oncology centre. RESULTS: The new
concentration solution of oxaliplatin achieves a 56% reduction
in preparation time, saving 139 seconds compared with the lyo-
philised powder (p < 0.001) and also is linked to less use of
consumables. Monetary savings linked to preparation time and
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consumables amount 0.84€ per preparation (0.48€ due to time
saving and 0.36€ linked to less use of consumables). For the case
of colorectal cancer standard chemotherapy regimen in adjuvant
(12 cycles) these savings could mean annually 10,080€ per 1,000
patients. CONCLUSION: The concentration solution, a new
presentation of oxaliplatin, has signiﬁcant advantages compared
with the traditional lyophilised powder. These advantages have
been measured as monetary savings linked to less preparation
time and use of consumables. In the future it would be of interest
to assess other advantages of concentrated solution chemothera-
pies over the more conventional ones like less errors of medica-
tion due to manipulation.
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OBJECTIVES: A recent randomized 2 ¥ 2 phase III trial com-
pared oral capecitabine + IV oxaliplatin (XELOX), IV 5-FU/LV/
oxaliplatin (FOLFOX-4), XELOX+bev, and FOLFOX-4+bev as
ﬁrst-line therapy for MCRC. FOLFOX-4 was the regulatory
control. XELOX was non-inferior to FOLFOX-4 for
progression-free survival, and bev-containing regimens were
superior to comparison arms. This economic analysis compared
expected costs in XELOX vs. FOLFOX-4 arms in an Italian
hospital setting from a payer and societal perspective.
METHODS: Direct medical and indirect cost estimates (for
patient time and travel) were compared. Resource use and
patient time were estimated based on trial data and protocols.
Data collected during the trial and used in the analysis were as
follows: no. of visits/duration of drug administration, central
venous access management, treatment of adverse events (AE)
including hospital days for treatment-related AEs and total hours
of ambulatory encounters. Unit costs were based on hospital
costs and other published sources. RESULTS: Total direct
medical cost estimates were higher for bi-weekly FOLFOX-4 vs.
3-weekly XELOX: €17,900 vs. €10,900. XELOX had higher
drug costs while FOLFOX-4 had higher drug administration
costs, with about 15 more visits on average per patient. Costs for
hospitalization and ambulatory encounters were slightly lower
for FOLFOX-4 (€500 vs. €800); other medications and venous
access were slightly higher for FOLFOX-4 (€5000 vs. €2000).
Similar patterns held for FOLFOX-4+bev vs. XELOX+bev (total
direct medical cost estimates €33,100 vs. €25,000). Indirect time
cost estimates were lower with XELOX due to fewer cycles and
visits: estimated savings range from €9,000–€11,000. CONCLU-
SION: XELOX is cost-saving from both payer and societal per-
spective in comparison to FOLFOX-4.
PCN39
THE COST OFTREATING AND MANAGING ABNORMAL
CERVICAL CONDITIONS IN IRELAND
Rash B1, Prendiville W2, Byrne P3, Stratton J4, Redmond S5
1Health Market International, Ann Arbor, MI, USA, 2Coombe Women’s
Hospital, Dublin, Ireland, 3Beaumont Hospital, Dublin, Ireland,
4Waterford Regional Hospital,Waterford, Ireland, 5GlaxoSmithKline,
Dublin 16, Ireland
OBJECTIVES: The objective of this study was to estimate Irish
speciﬁc costs for managing abnormal cervical conditions which
are required for cost-effectiveness analysis of prophylactic cervi-
cal cancer vaccination in Ireland. Methods: This was a retrospec-
tive study that collected resource utilisation and clinical outcome
data on 395 women attending four colposcopy clinics in Ireland.
Sampling was stratiﬁed to include 10%, 35%, 25%, 25% and
5% of women in the borderline, mild, moderate, severe and
cancer cytology groups respectively. Data were collected from the
date of referral until the latest treatment or the patient returned
to ‘normal’ cytology. Unit cost data, also collected during the
study, were applied to the utilisation data to estimate costs.
RESULTS: The mean age of all women with abnormal smears
was 31 years (range 18–68). The mean age of women with cancer
was 48 (range 23–68). The average cost of treating women who
initially had an abnormal smear but were subsequently observed
to be histologically negative without receiving treatment was
€317 (SD €147). The corresponding costs for women with CIN1,
CIN2 and CIN3 were €522 (SD €255), €673 (SD €237), and
€689 (SD €227) respectively. The average cost of treating invasive
cervical cancer was €10,449 (SD €4,952). The total cost of man-
aging abnormal cervical conditions was estimated at around €10
million per annum. CONCLUSION: Managing abnormal cervi-
cal conditions is expensive. Analysis in other countries found that
prophylactic cervical cancer vaccination is a cost effective way to
reduce these abnormalities [1]. This study will be used in a cost
effectiveness analysis of prophylactic cervical cancer vaccination
in Ireland. Reference: [1] Goldie SJ, et al. J Natl Cancer Inst
2004;96:604–15.
PCN40
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE
BLADDER CANCER MANAGEMENT:AN ECONOMIC MODEL
OFTHE IMPACT ON GERMAN HEALTH CARE COSTS
Sievert KD1, Zyczynski T2, Sweet A3, Rößler DW4, Stenzl A5
1Universitätsklinikum Tübingen,Tübingen, Germany, 2GE Healthcare,
Princeton, NJ, USA, 3GE Healthcare, Buckinghamshire, UK,
4Caritas-Krankenhaus St. Josef, Regensburg, Germany, 5University of
Tuebingen,Tübingen, Germany
OBJECTIVES: The purpose of this study was to estimate the
budget impact on the German health care service of using Hexvix
(hexaminolevulinate) cystoscopy in conjunction with white light
cystoscopy (WLC) in the management of non-invasive bladder
cancer (NIBC). Hexvix cystoscopy potentially allows more com-
plete detection and delineation of bladder cancer tumours com-
pared with standard WLC alone during transurethral resection of
the bladder (TURB). This can potentially lead to fewer tumour
recurrences through more effective tumour resection, and may
change patient management. METHODS: A model was devel-
oped to simulate the ﬂow of newly diagnosed bladder cancer
patients through treatment one year after diagnosis. Model
inputs, including procedure costs and clinical algorithms, are
based on the bladder cancer guidelines by the European Associa-
tion of Urology (EAU), literature review and German clinical
practice. Based on data obtained with an unlicensed and less
readily taken up ﬂuorescent molecule, a relative reduction in
recurrence rate is assumed in the model when compared to WLC.
RESULTS: The model predicts that Hexvix is associated with a
potential reduction in the number of procedures required com-
pared to WLC alone (801 cystectomies and 31,734 TURBs with
Hexvix compared to 881 and 33,823 with WLC alone) in the
ﬁrst year. This is estimated to result in a potential increase in
costs to the German health care system of 5.76% in the ﬁrst year,
compared to WLC alone in all newly diagnosed NIBC patients.
CONCLUSION: The model illustrates how Hexvix, when used
as an adjunct to WLC in TURB may result in the reduction of
invasive, time intensive, high cost procedures such as cystecto-
mies and TURBs, compared with WLC alone. Although the
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